French biotech EktaH lands €2.4M from Bpifrance to advance obesity drug
What's the deal? French biotech EktaHDealroom has a profile for this one. Try Dealroom → has secured €2.4 million in non-dilutive grant funding from Bpifrance, France's public investment bank, to advance its experimental oral obesity drug NKS-3 into Phase II clinical development.
The details: The money is split equally between grant funding and reimbursable advances, released in stages against annual milestones and regulatory progress. It will fund a 90-day toxicology study, manufacturing work, and further trials.
Why it matters: Backing from Bpifrance, a prominent state investor, lends institutional weight to a small startup pursuing a mechanism outside the dominant GLP-1 drug class. NKS-3 is an oral small molecule that reactivates fat taste receptors to trigger the body's own satiety hormones.
What's the endgame? EktaH has dosed the first patient in SERENITY-1, an exploratory Phase IIa trial in Tunisia enrolling about 31 adults with obesity. Topline results are expected in the first quarter of 2027.
The company is also preparing a larger Phase II programme in France testing NKS-3 both as a standalone treatment and as a way to maintain weight after patients stop GLP-1 therapy. One planned study would enrol roughly 100 adults.
What could go wrong? The grant is modest and milestone-dependent, not a large financing round. The Phase IIa study is exploratory, and Phase I results are still pending in Q1 2027 — so there is no clinical proof yet that NKS-3 works in people.
The signal: Obesity-drug investment is concentrating in far bigger programs — Corxel recently raised $287 million and AmbrosiaDealroom has a profile for this one. Try Dealroom → $100 million for oral candidates. EktaH's Phase II entry is a useful early marker for a small French player, but far from evidence it can compete.
Read more: indianpharmapost.com
Image credit: Generated with Gemini